United Therapeutics Corporation Revenues
United Therapeutics Corporation (UTHR) reported Revenues of $1.48 billion for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-24.
Discontinued › Income Statement
us-gaap:Revenues · last filed 2021-02-24
- United Therapeutics Corporation revenues for the quarter ending 2020-03-31 was $356.30M, a 1.74% decline year-over-year.
- United Therapeutics Corporation revenues for the quarter ending 2019-12-31 was $311.10M, a 18.43% decline year-over-year.
- United Therapeutics Corporation revenues for the quarter ending 2019-09-30 was $401.50M, a 2.71% decline year-over-year.
- United Therapeutics Corporation revenues for the quarter ending 2019-06-30 was $373.60M, a 15.95% decline year-over-year.
- United Therapeutics Corporation revenues for fiscal 2020 was $1.48B, a 2.38% increase from fiscal 2019.
- United Therapeutics Corporation revenues for fiscal 2019 was $1.45B, a 11.00% decline from fiscal 2018.
- United Therapeutics Corporation revenues for fiscal 2018 was $1.63B, a 5.65% decline from fiscal 2017.
- United Therapeutics Corporation revenues for fiscal 2017 was $1.73B, a 7.91% increase from fiscal 2016.
| Period end | Revenues 3 month | Revenues 3 month as first filed | Revenues 6 month | Revenues 6 month as first filed | Revenues 9 month | Revenues 9 month as first filed | Revenues 12 month | Revenues 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2020-12-31 | $1.48B 10-K · filed 2021-02-24 | |||||||
| 2020-03-31 | $356.30M 10-Q · filed 2020-04-29 | $667.40M derived: sum of 2 quarters · filed 2020-04-29 | $1.07B derived: sum of 3 quarters · filed 2020-04-29 | $1.44B derived: sum of 4 quarters · filed 2020-04-29 | ||||
| 2019-12-31 | $311.10M 10-K · filed 2020-02-26 | $712.60M derived: sum of 2 quarters · filed 2020-02-26 | $1.09B derived: sum of 3 quarters · filed 2020-02-26 | $1.45B 10-K · filed 2021-02-24 | ||||
| 2019-09-30 | $401.50M 10-K · filed 2020-02-26 | $775.10M derived: sum of 2 quarters · filed 2020-02-26 | $1.14B 10-Q · filed 2019-10-30 | $1.52B derived: sum of 4 quarters · filed 2020-04-29 | ||||
| 2019-06-30 | $373.60M 10-K · filed 2020-02-26 | $736.20M 10-Q · filed 2019-07-31 | $1.12B derived: sum of 3 quarters · filed 2020-04-29 | $1.53B derived: sum of 4 quarters · filed 2020-04-29 | ||||
| 2019-03-31 | $362.60M 10-Q · filed 2020-04-29 | $744.00M derived: sum of 2 quarters · filed 2020-04-29 | $1.16B derived: sum of 3 quarters · filed 2020-04-29 | $1.60B derived: sum of 4 quarters · filed 2020-04-29 | ||||
| 2018-12-31 | $381.40M 10-K · filed 2020-02-26 | $794.10M derived: sum of 2 quarters · filed 2020-02-26 | $1.24B derived: sum of 3 quarters · filed 2020-02-26 | $1.63B 10-K · filed 2021-02-24 | ||||
| 2018-09-30 | $412.70M 10-K · filed 2020-02-26 | $857.20M derived: sum of 2 quarters · filed 2020-02-26 | $1.25B 10-Q · filed 2019-10-30 | $1.71B derived: sum of 4 quarters · filed 2020-02-26 | ||||
| 2018-06-30 | $444.50M 10-K · filed 2020-02-26 | $833.70M 10-Q · filed 2019-07-31 | $1.30B derived: sum of 3 quarters · filed 2020-02-26 | $1.74B derived: sum of 4 quarters · filed 2020-02-26 | ||||
| 2018-03-31 | $389.20M 10-K · filed 2020-02-26 | $853.90M derived: sum of 2 quarters · filed 2020-02-26 | $1.30B derived: sum of 3 quarters · filed 2020-02-26 | $1.74B derived: sum of 4 quarters · filed 2020-02-26 | ||||
| 2017-12-31 | $464.70M 10-K · filed 2019-02-27 | $910.20M derived: sum of 2 quarters · filed 2019-02-27 | $1.35B derived: sum of 3 quarters · filed 2019-02-27 | $1.73B 10-K · filed 2020-02-26 | ||||
| 2017-09-30 | $445.50M 10-K · filed 2019-02-27 | $890.10M derived: sum of 2 quarters · filed 2019-02-27 | $1.26B 10-Q · filed 2018-10-31 | $1.67B derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-06-30 | $444.60M 10-K · filed 2019-02-27 | $815.10M 10-Q · filed 2018-08-01 | $1.22B derived: sum of 3 quarters · filed 2019-02-27 | $1.63B derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-03-31 | $370.50M 10-K · filed 2019-02-27 | $779.50M derived: sum of 2 quarters · filed 2019-02-27 | $1.19B derived: sum of 3 quarters · filed 2019-02-27 | $1.60B derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2016-12-31 | $409.00M 10-K · filed 2018-02-21 | $817.20M derived: sum of 2 quarters · filed 2018-02-21 | $1.23B derived: sum of 3 quarters · filed 2018-02-21 | $1.60B 10-K · filed 2019-02-27 | ||||
| 2016-09-30 | $408.20M 10-K · filed 2018-02-21 | $820.80M derived: sum of 2 quarters · filed 2018-02-21 | $1.19B 10-Q · filed 2017-10-25 | $1.59B derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2016-06-30 | $412.60M 10-K · filed 2018-02-21 | $781.60M 10-Q · filed 2017-07-27 | $1.19B derived: sum of 3 quarters · filed 2018-02-21 | $1.57B derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2016-03-31 | $369.00M 10-K · filed 2018-02-21 | $773.90M derived: sum of 2 quarters · filed 2018-02-21 | $1.16B derived: sum of 3 quarters · filed 2018-02-21 | $1.51B derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2015-12-31 | $404.90M 10-K · filed 2017-02-22 | $404.88M 10-K · filed 2016-02-25 | $791.10M derived: sum of 2 quarters · filed 2017-02-22 | $1.14B derived: sum of 3 quarters · filed 2017-02-22 | $1.47B 10-K · filed 2018-02-21 | $1.47B 10-K · filed 2016-02-25 | ||
| 2015-09-30 | $386.20M 10-K · filed 2017-02-22 | $386.22M 10-Q · filed 2015-10-27 | $733.40M derived: sum of 2 quarters · filed 2017-02-22 | $1.06B 10-Q · filed 2016-10-27 | $1.06B 10-Q · filed 2015-10-27 | $1.41B derived: sum of 4 quarters · filed 2017-02-22 | ||
| 2015-06-30 | $347.20M 10-K · filed 2017-02-22 | $347.16M 10-Q · filed 2015-07-28 | $674.70M 10-Q · filed 2016-07-28 | $674.66M 10-Q · filed 2015-07-28 | $1.02B derived: sum of 3 quarters · filed 2017-02-22 | $1.35B derived: sum of 4 quarters · filed 2017-02-22 | ||
| 2015-03-31 | $327.50M 10-K · filed 2017-02-22 | $327.50M 10-Q · filed 2015-04-28 | $673.86M derived: sum of 2 quarters · filed 2017-02-22 | $1.00B derived: sum of 3 quarters · filed 2017-02-22 | $1.33B derived: sum of 4 quarters · filed 2017-02-22 | |||
| 2014-12-31 | $346.36M 10-K · filed 2016-02-25 | $676.31M derived: sum of 2 quarters · filed 2016-02-25 | $999.12M derived: sum of 3 quarters · filed 2016-02-25 | $1.29B 10-K · filed 2017-02-22 | $1.29B 10-K · filed 2015-02-24 | |||
| 2014-09-30 | $329.95M 10-K · filed 2016-02-25 | $652.75M derived: sum of 2 quarters · filed 2016-02-25 | $942.16M 10-Q · filed 2015-10-27 | $1.23B derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-06-30 | $322.80M 10-K · filed 2016-02-25 | $612.21M 10-Q · filed 2015-07-28 | $901.22M derived: sum of 3 quarters · filed 2016-02-25 | $1.20B derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-03-31 | $289.40M 10-K · filed 2016-02-25 | $578.42M derived: sum of 2 quarters · filed 2016-02-25 | $880.64M derived: sum of 3 quarters · filed 2016-02-25 | $1.16B derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2013-12-31 | $289.02M 10-K · filed 2015-02-24 | $591.24M derived: sum of 2 quarters · filed 2015-02-24 | $871.85M derived: sum of 3 quarters · filed 2015-02-24 | $1.12B 10-K · filed 2016-02-25 | ||||
| 2013-09-30 | $302.23M 10-K · filed 2015-02-24 | $582.83M derived: sum of 2 quarters · filed 2015-02-24 | $827.97M 10-Q · filed 2014-10-28 | $1.07B derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2013-06-30 | $280.61M 10-K · filed 2015-02-24 | $525.74M 10-Q · filed 2014-07-29 | $769.56M derived: sum of 3 quarters · filed 2015-02-24 | $1.01B derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2013-03-31 | $245.14M 10-K · filed 2015-02-24 | $488.95M derived: sum of 2 quarters · filed 2015-02-24 | $731.42M derived: sum of 3 quarters · filed 2015-02-24 | $957.00M derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2012-12-31 | $243.82M 10-K · filed 2014-02-25 | $486.29M derived: sum of 2 quarters · filed 2014-02-25 | $711.86M derived: sum of 3 quarters · filed 2014-02-25 | $916.08M 10-K · filed 2015-02-24 | ||||
| 2012-09-30 | $242.47M 10-K · filed 2014-02-25 | $468.05M derived: sum of 2 quarters · filed 2014-02-25 | $672.26M 10-Q · filed 2013-10-29 | $867.44M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2012-06-30 | $225.58M 10-K · filed 2014-02-25 | $429.79M 10-Q · filed 2013-07-25 | $624.97M derived: sum of 3 quarters · filed 2014-02-25 | $826.71M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2012-03-31 | $204.21M 10-K · filed 2014-02-25 | $399.39M derived: sum of 2 quarters · filed 2014-02-25 | $601.13M derived: sum of 3 quarters · filed 2014-02-25 | $784.88M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2011-12-31 | $195.18M 10-K · filed 2013-02-26 | $396.92M derived: sum of 2 quarters · filed 2013-02-26 | $580.67M derived: sum of 3 quarters · filed 2013-02-26 | $743.18M 10-K · filed 2014-02-25 | ||||
| 2011-09-30 | $201.74M 10-K · filed 2013-02-26 | $385.49M derived: sum of 2 quarters · filed 2013-02-26 | $548.00M 10-Q · filed 2012-11-01 | $711.69M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2011-06-30 | $183.75M 10-K · filed 2013-02-26 | $346.26M 10-Q · filed 2012-07-26 | $509.95M derived: sum of 3 quarters · filed 2013-02-26 | $678.53M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2011-03-31 | $162.51M 10-K · filed 2013-02-26 | $165.62M 10-Q · filed 2011-04-28 | $326.20M derived: sum of 2 quarters · filed 2013-02-26 | $494.78M derived: sum of 3 quarters · filed 2013-02-26 | $629.50M derived: sum of 4 quarters · filed 2013-02-26 | |||
| 2010-12-31 | $163.69M 10-K · filed 2012-02-28 | $332.26M derived: sum of 2 quarters · filed 2012-02-28 | $466.99M derived: sum of 3 quarters · filed 2012-02-28 | $592.90M 10-K · filed 2013-02-26 | $603.83M 10-K · filed 2011-02-24 | |||
| 2010-09-30 | $168.57M 10-K · filed 2012-02-28 | $170.98M 10-Q · filed 2010-10-28 | $303.30M derived: sum of 2 quarters · filed 2012-02-28 | $429.21M 10-Q · filed 2011-10-27 | $437.35M 10-Q · filed 2010-10-28 | $527.16M derived: sum of 4 quarters · filed 2012-02-28 | ||
| 2010-06-30 | $134.72M 10-K · filed 2012-02-28 | $137.49M 10-Q · filed 2010-07-28 | $260.63M 10-Q · filed 2011-07-28 | $266.37M 10-Q · filed 2010-07-28 | $358.59M derived: sum of 3 quarters · filed 2012-02-28 | $455.81M derived: sum of 4 quarters · filed 2012-02-28 | ||
| 2010-03-31 | $125.91M 10-K · filed 2012-02-28 | $128.88M 10-Q · filed 2011-04-28 | $223.87M derived: sum of 2 quarters · filed 2012-02-28 | $321.08M derived: sum of 3 quarters · filed 2012-02-28 | $405.06M derived: sum of 4 quarters · filed 2012-02-28 | |||
| 2009-12-31 | $97.95M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-28 | $195.17M derived: sum of 2 quarters · filed 2012-02-28 | $279.15M derived: sum of 3 quarters · filed 2012-02-28 | $358.88M 10-K · filed 2012-02-28 | $369.85M 10-K · filed 2011-02-24 | |||
| 2009-09-30 | $97.22M 10-Q · filed 2010-10-28 | $181.19M derived: sum of 2 quarters · filed 2010-10-28 | $260.93M 10-Q · filed 2010-10-28 | |||||
| 2009-06-30 | $83.98M 10-Q · filed 2010-07-28 | $163.71M 10-Q · filed 2010-07-28 | ||||||
| 2008-12-31 | $281.50M 10-K · filed 2011-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |